ESPR

Esperion Therapeutics Stock Analysis

AI Rating

Good
  • Quality7/10
  • Growth↓ 4/10
  • Momentum↑ 9/10
Esperion Therapeutics sales and earnings growth
ESPR Growth
Neutral
  • Revenue Y/Y↓ 2.83%
  • EPS Y/Y↑ 12.90%
  • FCF Y/Y↓ -257.77%
Esperion Therapeutics gross and profit margin trends
ESPR Profitability
Neutral
  • Gross margin ↑ 58.20%
  • EPS margin↓ -34.80%
  • ROIC↓ -5.10%
Esperion Therapeutics net debt vs free cash flow
ESPR Risk
Great
  • Debt / Equity↓ -1.3
  • Debt / FCF↑ 5.5
  • Interest coverage↓ -0.3

Esperion Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗